Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

. CumsOnYourFeet69 has been discussing a new treatment called CosmeRNA which claims to target the root cause of male pattern baldness, and is considering using it in conjunction with Minoxidil instead of Finasteride due to possible side effects. Replies have highlighted that the efficacy of this treatment is still unknown, but it could be used as an effective maintenance option if successful.

The user experienced significant hair regrowth using topical finasteride/minoxidil and oral minoxidil/dutasteride, with some mild side effects that diminished over time. They plan to add microneedling to their regimen and have seen hair shedding cycles every six months, followed by thicker regrowth.

The conversation discusses using a custom topical from Skin Medicinals containing latanoprost for hair loss, which helps move hairs into the anagen phase. The user is curious about the cost and effectiveness of this treatment.

The post discusses the use of latanoprost foam for hair growth, with the user expressing concerns about its efficiency and safety. The user is currently using topical dutasteride, which maintains their hair but doesn't promote regrowth, and is seeking a product that doesn't affect hormone levels.

User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.

Piroctone olamine is more effective than ketoconazole for increasing hair growth and reducing itching and dandruff. Treatments discussed include Minoxidil, finasteride, and RU58841.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

The conversation discusses a study comparing microneedling combined with minoxidil versus biotin/panthenol for hair loss. Results suggest biotin/panthenol may be superior to minoxidil, though the sample size was small.

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.

CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

OP plans to switch from topical to oral minoxidil due to limited results and is advised to overlap both for a few weeks before discontinuing the topical. Oral minoxidil may be more effective for non-responders to topical treatment.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

The conversation is about someone planning to use cb-03-01 for hair loss because they experience side effects with other treatments like finasteride, minoxidil, and RU58841. They have not found progress pictures online and are considering sharing their own experience with cb-03-01, which is expensive.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

The conversation is about using Bimatoprost for hair growth, with concerns about potential side effects like eye color change and fat atrophy. Users discuss combining it with other treatments like Minoxidil and Finasteride, and sourcing Bimatoprost in bulk.

The conversation humorously discusses the use of pp405 for hair loss, with mentions of finasteride and minoxidil. Users joke about unusual side effects like growing extra body parts.

NMN shows promise in promoting hair growth by reducing oxidative stress and weakening androgens. It may be a beneficial addition to hair loss treatments like Minoxidil and Finasteride.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

PP405 is likely a scam, with concerns about its legitimacy and safety, as it may cause unintended tissue growth. Users suggest sticking to known treatments like finasteride and minoxidil.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

3aHSD enzyme's role in hair loss and a crowdfund for research. Goal: explore new treatments, study RU58841, and develop natural topical product.

Various hair growth treatments were discussed, including microneedling, bimatoprost, setipiprant, stemoxydine, PGE2, CB-03-01, WNT Beta-Catenin upregulators, KY19382, topical estrogen, IGF-1, GH, MK-677, oral castor oil, fisetin, resveratrol, cetrizine, and lactic acid. Users shared experiences and sources for these treatments, with some expressing interest in topical solutions and others noting the lack of FDA approval or scientific evidence for certain options.